Cadherin 1 germline mutation co-occurs with medullary thyroid cancer and choroid plexus papilloma: A case report and review of literature Authors: Vijay Nitturi, Sricharan Gopakumar, Hsiang-Chih Lu, Akash J. Patel Published: 2025 ABSTRACT Background: We describe the case of a 23-year-old woman with a history of medullary thyroid cancer (MTC) who presented with a choroid plexus papilloma (CPP) and review the literature regarding the co-occurrence of these two pathologies.Case Description: A 23-year-old woman with a history of MTC treated with thyroidectomy 3 months prior was referred to neurosurgery with an incidental fourth ventricular mass found on prior imaging of her neck. She presented to the clinic with intermittent headaches and underwent MRI which demonstrated a hyperintense, heterogeneously enhancing lobular mass at the obex of the fourth ventricle. She underwent suboccipital craniotomy and C1 laminectomy for resection of tumor with pathology revealing CPP. No somatic mutations unique to the tumor were found after targeted exome sequencing and tumor-normal paired analyses. Interestingly, germline sequencing reveals a mutation in the tumor suppressor Cadherin 1(CDH1).Conclusion: Mutations in CDH1 may play a role in an underlying predisposition toward the development of MTC and CPP. Current literature identifies no definitive connection between MTC and CPP, though future studies may suggest the role of this gene beyond a predisposition to gastric and breast cancer. INTRODUCTION Choroid plexus papilloma (CPP) is a rare, benign tumor that arises from the choroid plexus epithelium.[13] Medullary thyroid cancer (MTC) is a rare form of thyroid cancer originating from the parafollicular C-cells of the thyroid gland.[9] In this article, we describe the case of a 23-year-old woman with a history of MTC who was also found to have a fourth ventricular CPP and review the literature regarding the co-occurrence of these two pathologies. CASE DESCRIPTION A 23-year-old woman underwent thyroidectomy for treatment of MTC (T3N1bM0) [Figure 1]. She did not have a family history of thyroid disease, thyroid cancer, or any other cancers. Three months later, she was referred to neurosurgery after routine CT imaging of her neck showed a fourth ventricular mass. The patient reported intermittent headaches but denied any motor weakness, gait issues, vision issues, swallowing issues, or dizziness. At this time, her calcitriol level had declined from >9000 to 16 pg/mL (normal <7.7), and her thyroid panel postthyroidectomy showed a normal free T4 and a slightly elevated thyroid stimulating hormone at 4.5 uiu/mL (normal 0.4–4.1) treated with daily levothyroxine. She had no focal neurological deficits on physical examination. MRI revealed a lobular mass at the obex of the fourth ventricle that protruded slightly into the foramen magnum along the posterior cervicomedullary junction [Figures 2a and b]. (a and b) Postcontrast sagittal and axial CT revealed a large hyperintense, homogeneously enhancing mass in the left lobe of the thyroid gland with scattered speckled calcifications (see arrows). An incidental note is also made of a lesion at the obex of the fourth ventricle on the sagittal imaging. (c and d) On hematoxylin & eosin staining, the thyroid tumor has a nested architecture. The tumor cells are round to focally spindled and have round nuclei with focal mild pleomorphism and abundant cytoplasm (Scale bar = 50 μm, 20x Magnification). (a and b) Postcontrast sagittal and axial MRI revealed a hyperintense, heterogeneously enhancing lobular mass at the obex of the fourth ventricle without hydrocephalus (see arrows). The mass slightly protrudes through the foramen magnum along the posterior cervicomedullary junction with local mass effect. (c) On hematoxylin & eosin staining, the brain tumor shows a papillary neoplasm with no significant atypia , 20x Magnification. (d) Transthyretin (prealbumin) is positive in the tumor consistent with choroid plexus papilloma (Scale bar = 50 μm, 20x Magnification). Differential diagnoses included ependymoma, CPP, choroid plexus carcinoma, subependymoma, meningioma, medulloblastoma, astrocytoma, and hemangioblastoma. In addition, complete neuroaxis imaging was obtained and did not reveal any additional lesions. Radiographically, CPPs have round or oval contours with variable to avid contrast enhancement on MRI and often contain calcifications.[14] While this tumor exhibited only mild, heterogeneous enhancement, there was a clear attachment to the choroid plexus. Ultimately, histopathological testing is necessary to confirm a diagnosis of CPP given the wide differential.[14] The patient underwent an elective suboccipital craniotomy and C1 laminectomy for the resection of tumor. Histopathological examination of the brain tumor showed a papillary neoplasm with scattered microcalcifications. The tumor cells were diffusely positive for glial fibrillary acidic protein and transthyretin, and they were positive for CK7. These findings were most consistent with a CPP [Figures 2cd]. Postoperative MRI demonstrated gross total resection [Figure 3]. (a and b) T1-weighted postcontrast sagittal and axial MRI imaging demonstrates complete resection of the 4th ventricle choroid plexus papilloma. Targeted exome sequencing of the tumor sample by TEMPUS xT genome profiling, interrogating 648 cancer-related genes, revealed no somatic mutations unique to the tumor among these genes after comparison with saliva for tumor-normal tissue paired analysis.[2] Germline sequencing of blood tested with the Invitae multi-cancer gene panel was negative for RET and TP53 mutations; however, a heterozygous variant of uncertain significance in cadherin 1 (CDH 1) (exon 15, c.2427T>A, p.Asn908Lys) was identified.[7] Three protein function prediction tools were used to assess this mutation: Sorting Intolerant from Tolerant (SIFT), Polymorphism Phenotyping Version 2 (PolyPhen-2), and Align-Grantham Variation and Grantham Difference (Align-GVGD). The SIFT and PolyPhen-2 algorithms both classified this missense mutation as deleterious and probably damaging, respectively.[5] Align-GVCD, however, prognosticated that this mutation is less likely to interfere with function.[15] While two out of three prediction tools considered this mutation to be protein function-altering, conflicting in silico predictions resulted in this CDH1 mutation’s classification as a variant of unknown significance. At 36-month postthyroidectomy and 33-month postcraniotomy, the patient has not had recurrence of CPP or medulary thyroid cancer (MTC). Additional nodules of undetermined significance were identified in the liver concerning for cysts, and vertebral column likely representing hemangioma, and in the lung of unknown etiology. All lesions were stable over 1 year and less likely to be considered metastatic in nature at this time per oncology and radiology, with a plan for continued surveillance. Calcitriol and thyroid panel testing remain normal. CASE DISCUSSION Here, we present a case of co-occurrence of MTC and CPP in a patient with a germline mutation in CDH1. CPP is an extremely rare, benign brain tumor, representing only 0.3–0.6% of all intracranial tumors.[13] MTC is also a very rare form of cancer, comprising just 4% of all thyroid tumors.[9] Co-occurrence of both pathologies in the same patient has an exceedingly low probability. A comprehensive literature search in PubMed and Embase revealed no prior cases with co-occurring MTC and CPP or any germline mutations in CDH1 underlying MTC or CPP. CDH1, the gene that encodes for E-cadherin, is a known tumor suppressor that is mutated in diffuse gastric and lobular breast cancer.[4] CDH1 mutations have rarely been associated with gliomas but have not been observed in cases of CPP.[6] In addition, while CDH1 and RET, the most mutated gene in MTC, converge on PI3K/Akt pathway activation, no direct links between CDH1 and RET have been established.[1,12] Mechanistically, CDH1 can be hypermethylated in CPPs, with one paper reporting a fourth ventricular choroid plexus papilloma with CDH1, RARB, and SFN gene hypermethylation.[11] CDH1 inactivation is known to activate the Wnt signaling pathway, which has been implicated in the tumorigenesis of CPPs.[8] Loss of TP53, a tumor suppressor that regulates the Wnt signaling pathway, has been previously observed in MTC.[3,10] A possible hypothesis that explains the development of CPP in this patient could be a “twohit” mechanism, where somatic hypermethylation of CDH1 co-occurring with a germline mutation in CDH1 results in tumorigenesis. CONCLUSION In summary, we present the first case of co-occurrence of MTC and CPP. We find a novel germline mutation in CDH1 in this patient, prompting the need for a larger investigation into the co-occurrence of CPPs and MTC in patients with germline CDH1 mutations.